CV · CapsoVision, Inc
Substantial doubt about the company's ability to continue as a going concern.
“The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company raised approximately $14 million in gross proceeds resulting from subsequent Private Placement described in Note 1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE and further discussed in Note 9. COMMON STOCK, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.”View the 10-Q filed May 14, 2026
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| CapsoCam Plus® patients | 167,000 | as of March 31, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CV
this stock
CapsoVision, Inc
|
$324.26M | -38.3% | — | 5.0 | 4.2% |
|
ABT
Abbott Laboratories
|
$179.51B | -19.2% | +5.7% | 28.9 | 1.4% |
|
SYK
Stryker Corp
|
$126.60B | -9.0% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$106.51B | -13.9% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.77B | -54.3% | +5.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CV | +3.3% | -6.9% | +21.8% | -12.9% | -38.3% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +5.0% | -7.6% | +15.4% | -11.8% | -46.5% |